RELIEF THERAPEUTICS Holding has entered into has entered into a definitive agreement for the sale and purchase in a private placement of 1.5m Relief shares and warrants to purchase up to 1.5m Relief shares. The
Tags :Robert Bernet
Innovad, a provider of animal nutrition and health solutions, has acquired its Swiss competitor Herbonis and its subsidiaries in Switzerland, France and including Wyreside in the UK. The acquisition aims to strengthen Innovad’s portfolio
As we have informed here, Suixx sold the db electronic Group to NCAB Group, which is listed on Nasdaq Stockholm. The db electronic Group is active in the development, production, distribution and trading of printed
As we have informed last 15 November 2022 here, Hangzhou GreatStar Industrial, whose A Shares are listed on the Shenzhen Stock Exchange, became the eighth Chinese company that has listed global depositary receipts (GDRs) on the SIX
There is a merger in cruise brokerage. The two Swiss tourism companies e-hoi and Cruise Center also want to strengthen their bargaining power with the cruise lines. Business, down during the pandemic, is picking up
HomeToGo announced the acquisition of Frankfurt-based internet company e-domizil from e-vacation Group Holding for €40 million. The purchase price includes a payment of around €2 million in class A shares owned by HomeToGo, which is subject to
Mainova, an energy supplier based in Frankfurt am Main, has acquired a majority stake in the Bavarian energy service provider mobiheat, including its subsidiaries in Austria and Switzerland, from Energieversorgung Offenbach (EVO) and the mobiheat
Relief Therapeutics, a biopharmaceutical company, has launched a Level 1 American Depositary Receipt (“ADR”) program in the United States. From 18 November 2021, ADRs can be traded over-the-counter. Relief’s ADR program complements the existing main listing of
Biopharmaceutical company Relief Theraputics Holding, has a binding agreement with two institutional U.S. investors completed. The contract provides for the purchase of Relief shares with a total value of CHF 15 million, which come from
Relief Therapeutics Holding, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, has issued 1,000,000,000 additional registered shares out of the authorised share capital approved by the Annual
